LGND LIGAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%
Margins
Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%
Returns
ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x
Cash quality & payout
Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $268.09M | $167.13M |
| R&D expense | $81.18M | $21.43M |
| SG&A expense | $92.45M | $78.65M |
| Operating income | $41.00M | -$22.61M |
| Interest expense | $4.71M | $3.04M |
| Pretax income | $158.96M | $2.52M |
| Income tax | $34.51M | $6.55M |
| Net income | $124.45M | -$4.03M |
| EBITDA | $74.78M | $12.63M |
| EPS (basic) | 6.44 | -0.22 |
| EPS (diluted) | 6.13 | -0.22 |
| Weighted avg. shares (diluted) | 20.29M | 18.29M |
| Balance sheet | ||
| Cash & equivalents | $174.93M | $72.31M |
| Short-term investments | $558.59M | $183.86M |
| Receivables | $59.60M | $38.38M |
| Inventory | $9.13M | $14.11M |
| Current assets | $832.27M | $331.56M |
| PP&E, net | $3.57M | $15.13M |
| Goodwill | $101.54M | $105.25M |
| Intangibles | $225.44M | $266.65M |
| Total assets | $1.56B | $941.77M |
| Current liabilities | $37.45M | $37.11M |
| Long-term debt | $446.19M | $0 |
| Total debt | $446.19M | $0 |
| Total liabilities | $543.42M | $111.33M |
| Shareholders' equity | $1.02B | $830.44M |
| Net debt | $271.26M | -$72.31M |
| Shares outstanding | 19.77M | 19.11M |
| Cash flow statement | ||
| Operating cash flow | $49.36M | $97.05M |
| Capital expenditure | $452,000 | $1.82M |
| Free cash flow | $48.91M | $95.23M |
| Investing cash flow | -$377.32M | -$143.66M |
| Financing cash flow | $428.22M | $97.14M |
| Depreciation & amortization | $33.77M | $35.24M |
| Stock-based compensation | $46.85M | $41.09M |
| Share buybacks | $15.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.